

Tranexamic Acid – A Brief Review and Update

John R Tuttle*

Department of Orthopedic Surgery, Warren Alpert Medical School of Brown University, USA

*Corresponding author: John R Tuttle, Department of Orthopedic Surgery, Warren Alpert Medical School of Brown University, USA, Tel: +1 408-816-2779; Fax: +1 408-837-0557; E-mail: tuttle.78@gmail.com

Received date: 22 Apr 2016; Accepted date: 24 Jun 2016; Published date: 28 Jun 2016.

Citation: Tuttle JR (2016) Tranexamic Acid – A Brief Review and Update. *J Blood Disord Med* 1(3): doi <http://dx.doi.org/10.16966/2471-5026.109>

Copyright: © 2016 Tuttle JR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Tranexamic acid (TXA) has been in use world-wide for over 50 years to help reduce blood loss and transfusion rates. TXA is an antifibrinolytic that has found a growing interest in multiple surgical fields, especially in Orthopedics over the past decade. As the evidence and applications continue to expand, it is important to understand the role this drug is playing in the care of patients. The purpose of this publication is to briefly summarize the history of TXA, its development, its current applications, and future directions for exploration.

Keywords: Tranexamic acid; TXA; Antifibrinolytic; Transfusion; Blood-loss; Review; History

Hemorrhage and exsanguination have continued to stymie physicians and surgeons despite all of the advancements of scientific medicine. Transfusion remains a mainstay of treatment; however cost and risk persist and limit our willingness to be satisfied with this tool alone. Tranexamic acid (trans-4-[aminomethyl] cyclohexane carboxylic acid) figure 1 or TXA is a synthetic lysine derivative that was developed in Japan by Shosuke and his wife Utako Okamoto in 1962. It is an antifibrinolytic that competitively inhibits lysine-binding sites on plasminogen molecules. This prevents the activation of plasmin and thus preserves the function of fibrin in clot formation. At higher concentrations, TXA also noncompetitively inhibits the binding of plasmin to fibrin, further preserving formed clot. Lysine by the same mechanism displays antifibrinolytic properties, which was the reason it provided a reasonable synthetic platform. E-aminocaproic acid was originally created by modifying lysine, leading to a nearly 10-fold increase in antifibrinolytic activity. This drug was marketed world-wide for its ability to reduce bleeding. In comparison, TXA is nearly ten times more effective than E-aminocaproic acid. Bleeding is thereby reduced by shifting the clotting/fibrinolysis balance in favor of clotting by a much more potent molecule [1]. Synovial fluid is a transudate of serum and small molecules typically diffuse across the synovial membrane unimpeded. TXA similarly crosses from the bloodstream into synovial fluid and reaches equilibrium with serum concentrations when administered intravenously [2]. It undergoes glomerular filtration via the kidneys without chemical modification, active excretion or absorption. Nearly 95% of the dose is excreted through the urine by 48 hours. The IV half-life is between 2-3 hours and the oral bioavailability is 30-50% [3]. Since its creation, TXA has proven useful in neurosurgery, urologic surgery, obstetrics and gynecology, trauma and trauma surgery, as well as orthopedic surgery [4]. The effectiveness of TXA in reducing bleeding in surgical and trauma patients has been repeatedly demonstrated [5,6,7].

The safety profile of TXA is very good, there are no reports of allergy or anaphylaxis, however its use may carry risk [2]. There is evidence in the trauma population that giving TXA over three hours after the onset of significant hemorrhage may contribute to increased mortality [8,9]. In addition, multiple reports have surfaced of intrathecal TXA leading to the production of seizures [10,11]. It is proposed that TXA exerts a GABA receptor antagonistic effect and thereby in higher concentrations may lead to seizure [12].

Thromboembolic events continue to be a concern as well. A review of the literature performed by Chan et al. [13]. found no conclusive evidence that TXA contributes to thromboembolic events. Instead they speculate that patients' pre-existing thrombophilia conditions combined with procoagulant factors are the underlying cause of thromboembolic events in patients that receive TXA. They conclude however that patients with known thrombophilia should be approached with caution when considering TXA administration. The known risks of TXA encourage scrutiny in its application, which continues to expand.

TXA use has found renewed and new interest in multiple fields, including cardiac surgery, spine surgery, obstetrics and gynecology, and orthopedics [14-17]. The indications and data supporting them are rapidly increasing. Orthopedics especially has seen an explosion in interest in this drug over the past decade. Evidence continues to mount for its routine application in the field.

Application in Orthopedic Surgery

The current use of TXA in orthopedic surgery lies largely in spine surgery, total joint arthroplasty and trauma. There may be applications in other sub-specialties, however this remains undetermined.




Figure 1: Molecular structure of tranexamic acid, a synthetic lysine derivative.

Spinal surgery may lead to excessive blood loss, especially in large deformity correction and multi-level fusions. Multiple clinical trials have demonstrated a consistent reduction in blood loss and in some instances, significant transfusion reduction [18,19]. Postoperative complications remained unaffected by TXA administration in these trials. Despite its widespread use in spine surgery, there is no consensus regarding the dose and timing of TXA administration [20].

Total joint arthroplasty literature has erupted with studies providing ample evidence for TXA in arthroplasty surgery. Research continues to attempt to pin down the best way to implement it. TXA has been administered via oral, intravenous, and topical routes. It is unclear which method of administration is most efficacious and safe [21]. While concern may persist regarding IV administration of TXA, large-scale clinical trials have not found any increase in adverse events [22,23]. Routine use in arthroplasty surgery has proven to be cost-effective as well by reducing transfusion rate [24,25]. All patients receiving a primary total hip or knee stand to benefit from TXA regardless of sex, age, BMI, or preoperative hemoglobin level [26,27]. Both IV and topical applications are effective in reducing blood loss and transfusions in this population [28,29]. At this time, it is clear that TXA should be routinely used during arthroplasty surgery. What remains unknown is the best protocol to adopt. A recent study demonstrated that oral TXA may be just as effective as IV TXA in total joint arthroplasty transfusion reduction. With oral TXA being significantly cheaper than IV dosing, this may lead to a shift in route administration in the future.

With its success in total joint arthroplasty, the extension of TXA use into hip fracture surgery, especially hemiarthroplasty (partial hip replacement) was inevitable. Multiple studies have found a reduction in blood loss and transfusion rates when TXA was used [30,31]. This is of particular interest in this patient population as they are more susceptible to anemia and its adverse effects. In addition, these patients lose a significant amount of blood prior to surgery and thus are more likely to require transfusion compared to those undergoing elective surgery [32]. Another consideration in these patients is the fact that they retain native cartilage in their hip. Recent in vitro data indicate that TXA can damage cartilage and is chondrotoxic at concentrations ≥ 50 mg/ml [33]. Further data is required to draw clinically relevant conclusions regarding the effect of TXA on cartilage.

Tranexamic acid has proven it belongs in the physician's armamentarium to reduce blood loss and prevent transfusions. While a great deal is known about TXA and its benefits, much remains to be discovered regarding the best practice for its implementation and the full breadth of its application.

Disclosure

The author has no disclosures, no conflicts of interest regarding this publication.

References

- Okamoto S, Okamoto U (1962) Amino-methyl-cyclohexane-carbolic acid: AMCHA. A new potent inhibitor of fibrinolysis. *Keio J Med* 11: 105-115.
- Ahlberg A, Eriksson O, Kjellman H (1976) Diffusion of tranexamic acid to the joint. *Acta Orthop Scand* 47: 486-488.
- Eriksson O, Kjellman H, Pilbrant A, Schannong M (1974) Pharmacokinetics of tranexamic acid after intravenous administration to normal volunteers. *Eur J Clin Pharmacol* 7: 375-380.
- McCormack PL (2012) Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. *Drugs* 72: 585-617.
- Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, et al. (2007) Antifibrinolytic use for minimising perioperative allogeneic blood transfusion. *Cochrane Database Syst Rev* CD001886.
- The CRASH-2 Collaborators (2010) Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomized, placebo-controlled trial. *Lancet* 376: 23-32.
- Ker K, Prieto-Merino D, Roberts I (2013) Systematic Review, Meta-analysis and Meta-regression of the Effect of Tranexamic Acid on Surgical Blood Loss. *Br J Surg* 1271-1279.
- The CRASH-2 Collaborators (2011) The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomized controlled trial. *Lancet* 377: 1096-1101.
- Valle EJ, Allen CJ, Van Haren RM, Jouria JM, Li H, et al. (2014) Do all trauma patients benefit from tranexamic acid? *J Trauma Acute Care Surg* 76: 1373-1378.
- Yeh HM, Lau HP, Lin PL, Sun WZ, Mok MS, et al. (2003) Convulsions and refractory ventricular fibrillation after intrathecal injection of a massive dose of tranexamic acid. *Anesthesiology* 98: 270-272.
- Mohseni K, Jafari A, Nobahar MR, Arami A (2009) Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia. *Anesth Analg* 108: 1984-1986.
- Furtmüller R, Schlag MG, Berger M, Hopf R, Huck S, et al. (2002) Tranexamic Acid, a Widely Used Antifibrinolytic Agent, Causes Convulsions by a γ -Aminobutyric Acid_A Receptor Antagonistic Effect. *J Pharmacol Exp Ther* 301: 168-173.
- Chan FC, Lau KK, Chan AKC, Chan HHW (2013) Tranexamic Acid is a Weak Provoking Factor For Thromboembolic Events: A Systematic Review Of The Literature. *Blood* 122: 3629-3629.
- Murphy GJ, Mango E, Lucchetti V, Battaglia F, Catapano D, et al. (2006) A randomized trial of tranexamic acid in combination with cell salvage plus a meta-analysis of randomized trials evaluating tranexamic acid in off-pump coronary artery bypass grafting. *J Thorac Cardiovasc Surg* 132: 475-480.
- Yang B, Li H, Wang D, He X, Zhang C, et al. (2013) Systematic review and meta-analysis of perioperative intravenous tranexamic acid use in spinal surgery. *PLoS One* 8: e55436.
- Ducloy-Bouthors A-S, Jude B, Duhamel A, Broisin F, Huissoud C, et al. (2011) Highdose tranexamic acid reduces blood loss in postpartum haemorrhage. *Crit Care* 15: R117.
- Danninger T, Memtsoudis SG (2015) Tranexamic acid and orthopedic surgery-the search for the holy grail of blood conservation. *Ann Transl Med* 3: 77.
- Farrokhi MR, Kazemi AP, Eftekharian HR, Akbari K (2011) Efficacy of prophylactic low dose of tranexamic acid in spinal fixation surgery: a randomized clinical trial. *J Neurosurg Anesthesiol* 23: 290-296.
- Raksakietisak M, Sathitkammanee B, Srisaen P, Duangrat T, Chinachoti T, et al. (2015) Two Doses of Tranexamic Acid Reduce Blood Transfusion in Complex Spine Surgery: A Prospective Randomized Study. *Spine* 40: E1257-E1263.
- Elwatidy S, Jamjoom Z, Elgamel E, Zakaria A, Turkistani A, et al. (2008) Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study. *Spine* 33: 2577-2580.
- KagomaYK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, et al. (2009) Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. *Thromb Res* 123: 687-696.
- Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, et al. (2014) Tranexamic acid use and postoperative outcomes in patients under-going total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. *BMJ* 349: g4829.

23. Wei Z, Liu M (2015) The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases. *Transfus Med* 25: 151-162.
24. Tuttle J, Ritterman S, Cassidy D, Anazonwu W, Froehlich J, et al. (2014) Cost Benefit Analysis of Topical Tranexamic Acid in Primary Total Hip and Knee Arthroplasty. *J Arthroplasty* 29: 1512-1515.
25. Gillette BP, Maradit Kremers H, Duncan CM, Smith HM, Trousdale RT, et al. (2013) Economic Impact of Tranexamic Acid in Undergoing Primary Total Hip and Knee Arthroplasty. *J Arthroplasty* 28: 137-139.
26. Tuttle J, Anazonwu W, Rubin L (2014) Subgroup Analysis of Topical Tranexamic Acid in Total Knee Arthroplasty. *Reconstructive Review*.
27. Anazonwu W, Tuttle J, Rubin L (2015) Subgroup Analysis of Topical Tranexamic Acid in Primary Total Hip Arthroplasty. *Reconstructive Review*.
28. Seo JG, Moon YW, Park SH, Kim SM, Ko KR, et al. (2013) The Comparative Efficacies of Intra-Articular and IV Tranexamic Acid for Reducing Blood Loss during Total Knee Arthroplasty. *Knee Surg Sports Traumatol Arthrosc* 21: 1869-1874.
29. Ueno M, Sonohata M, Fukumori N, Kawano S, Kitajima M, et al. (2016) Comparison between topical and intravenous administration of tranexamic acid in primary total hip arthroplasty. *J Orthop Sci* 21: 44-47.
30. Lee C, Freeman R, Edmondson M, Rogers BA (2015) The efficacy of tranexamic acid in hip hemiarthroplasty surgery: an observational cohort study. *Injury* 46: 1978-1982.
31. Emara WM, Moez KK, Elkhoully AH (2014) Topical versus intravenous tranexamic acid as a blood conservation intervention for reduction of post-operative bleeding in hemiarthroplasty. *Anesth Essays Res* 8: 48-53.
32. Zufferey PJ, Miquet M, Quenet S, Martin P, Adam P, et al. (2010) Tranexamic acid in hip fracture surgery: a randomized controlled trial. *Br J Anaesth* 104: 23-30.
33. Tuttle J, Feltman P, Ritterman S, Ehrlich MG (2015) Effects of Tranexamic Acid Cytotoxicity on *in vitro* Chondrocytes. *Am J Orthop (Belle Mead NJ)* 44: E497-E502.